warrenhochfeld

Dynavax breakout ahead of Heplisav approval

Long
NASDAQ:DVAX   Dynavax Technologies Corporation
Start of final bull run ahead of 9th November FDA announcement of Heplisav approval
$25-$30 price projection
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.